Atomo Diagnostics has responded to an ASX price query following unusual trading activity, denying any undisclosed price-sensitive information while acknowledging a related FDA update involving Lumos Diagnostics.
- Atomo denies undisclosed price-sensitive information amid recent trading surge
- Acknowledges Lumos Diagnostics' FDA response on FebriDx® CLIA waiver application
- FebriDx® test uses Atomo's patented Pascal cassette technology
- Atomo unable to assess impact of FDA response on its business currently
- Confirms compliance with ASX Listing Rules and board approval of response
Context of the Price Query
Atomo Diagnostics Limited (ASX:AT1) has issued a formal response to the Australian Securities Exchange (ASX) following a price query triggered by a notable increase in its share price and trading volume on 25 March 2026. The ASX sought clarity on whether Atomo was aware of any undisclosed price-sensitive information that might explain the recent market activity.
In its reply, Atomo firmly stated it is not aware of any such information that has not already been announced to the market. This assertion aims to reassure investors and regulators that the company remains compliant with continuous disclosure obligations under ASX Listing Rule 3.1.
Link to Lumos Diagnostics and FDA Update
While Atomo denies holding undisclosed material information, it acknowledged the recent trading halt by Lumos Diagnostics Holdings Ltd (ASX:LDX). Lumos is awaiting a decision from the U.S. Food and Drug Administration (FDA) regarding the Clinical Laboratory Improvement Amendments (CLIA) waiver application for its FebriDx® test. This test exclusively incorporates Atomo’s patented Pascal cassette technology, which enhances usability and reliability.
Atomo noted that it does not have details of the FDA’s response at this stage and therefore cannot yet determine the potential impact on its own operations or financial outlook. The company committed to ongoing engagement with Lumos and promised to update the market as soon as further information becomes available.
Compliance and Market Implications
Importantly, Atomo confirmed full compliance with the ASX Listing Rules, particularly the continuous disclosure requirements. The company’s board has authorised and approved the response to the ASX’s inquiries, underscoring governance discipline amid heightened market attention.
The recent price movement and volume spike in Atomo’s shares appear to be linked to market speculation around the Lumos FDA announcement rather than any direct undisclosed developments within Atomo itself. This dynamic highlights the interconnected nature of technology licensing and regulatory outcomes in the healthcare diagnostics sector.
Looking Ahead
Investors will be watching closely for Lumos’s FDA update and any subsequent disclosures from Atomo. The outcome could influence Atomo’s licensing revenues and strategic positioning, given the centrality of its patented technology to FebriDx®. Meanwhile, the company’s transparent communication helps maintain market confidence during this period of uncertainty.
Bottom Line?
Atomo’s clear disclosure stance sets the stage for market watchers to focus on Lumos’s FDA news and its ripple effects.
Questions in the middle?
- What will be the FDA’s final decision on Lumos’s FebriDx® CLIA waiver application?
- How might the FDA outcome affect Atomo’s licensing revenue and future partnerships?
- When can Atomo provide a more definitive update on the impact of Lumos’s regulatory developments?